- Home
- LXEO vs CATX Comparison
LXEO vs CATX Comparison
Compare LXEO & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXEO | CATX |
|---|---|---|
| Founded | 2017 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.7M | 355.0M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LXEO | CATX |
|---|---|---|
| Price | $3.56 | $2.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 16 |
| Target Price | ★ $20.30 | $12.29 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $654,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.98 | $1.96 |
| 52 Week High | $10.99 | $6.16 |
Technical Indicators
Market Signals| Indicator | LXEO | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 29.79 | 43.43 |
| Support Level | N/A | $2.44 |
| Resistance Level | $5.38 | $3.00 |
| Average True Range (ATR) | 0.26 | 0.16 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 27.86 | 40.68 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.